Cargando…

Effect of Pioglitazone in Preventing In-Stent Restenosis after Percutaneous Coronary Intervention in Patients with Type 2 Diabetes: A Meta-Analysis

BACKGROUND: The benefits of pioglitazone in patients with type 2 diabetes mellitus (T2DM) after percutaneous coronary intervention (PCI) is unclear. OBJECTIVES: To evaluate the effect of pioglitazone on prevention of in-stent restenosis (ISR) in patients with T2DM after PCI. METHODS: All full-text p...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zhao, Shi-jie, Zhong, Zhao-shuang, Qi, Guo-xian, Shi, Li-ye, Chen, Ling, Tian, Wen
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2016
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4862640/ https://www.ncbi.nlm.nih.gov/pubmed/27163676 http://dx.doi.org/10.1371/journal.pone.0155273

Ejemplares similares

In stent restenosis after percutaneous coronary intervention
por: Eyüboğlu, Mehmet
Publicado: (2016)

Effect of Pioglitazone on In-Stent Restenosis after Coronary Drug-Eluting Stent Implantation: A Meta-Analysis of Randomized Controlled Trials
por: Zhang, Ming-duo, et al.
Publicado: (2014)

Predictive Value of COPD History on In-Stent Restenosis in Coronary Arteries Following Percutaneous Coronary Intervention
por: Hou, Ling, et al.
Publicado: (2023)

New predictors of in-stent restenosis in patients with diabetes mellitus undergoing percutaneous coronary intervention with drug-eluting stent
por: Wang, Jian-Long, et al.
Publicado: (2018)

Impact of anemia on in-stent restenosis after percutaneous coronary intervention
por: Hu, Huilin, et al.
Publicado: (2021)

Systematic Review of Chinese Herbal Medicines for Preventing in-Stent Coronary Restenosis after Percutaneous Coronary Intervention
por: Zheng, Guo-Hua, et al.
Publicado: (2012)

The number of stents was an independent risk of stent restenosis in patients undergoing percutaneous coronary intervention
por: Tang, Long, et al.
Publicado: (2019)

Impact of hyperuricemia on clinical outcomes after percutaneous coronary intervention for in-stent restenosis
por: Joo, Hyung Joon, et al.
Publicado: (2018)

An analysis of factors related to the development of in-stent restenosis after percutaneous coronary intervention
por: Zhang, Gai, et al.
Publicado: (2020)

Risk factors associated with intra-stent restenosis after percutaneous coronary intervention
por: Alexandrescu, Dan-Mihai, et al.
Publicado: (2021)

In-stent restenosis after percutaneous coronary intervention: emerging knowledge on biological pathways
por: Pelliccia, Francesco, et al.
Publicado: (2023)

Calculating the overall risk of within-stent restenosis after multilesion percutaneous coronary intervention
por: Parviz, Yasir, et al.
Publicado: (2013)

An analysis of factors related to the development of in-stent restenosis after percutaneous coronary intervention: Retraction
Publicado: (2020)

Triglyceride-glucose index is associated with in-stent restenosis in patients with acute coronary syndrome after percutaneous coronary intervention with drug-eluting stents
por: Zhu, Yong, et al.
Publicado: (2021)

Incidence and risk factors of in-stent restenosis after percutaneous coronary intervention in patients from southern China
por: Li, Mingrui, et al.
Publicado: (2022)

Outcomes of Percutaneous Coronary Intervention for In‐Stent Restenosis Versus De Novo Lesions: A Meta‐Analysis
por: Elbadawi, Ayman, et al.
Publicado: (2023)

Arterial stiffness in patients with coronary artery disease: relation with in-stent restenosis following percutaneous coronary intervention
por: Prskalo, Zrinko, et al.
Publicado: (2016)

Effects of Low Dose Pioglitazone on Restenosis and Coronary Atherosclerosis in Diabetic Patients Undergoing Drug Eluting Stent Implantation
por: Lee, Hye Won, et al.
Publicado: (2013)

SOCS1 gene promoter methylation status is associated with in-stent restenosis after percutaneous coronary intervention
por: Zhou, Liang, et al.
Publicado: (2017)

Platelet Distribution Width on Admission Predicts In-Stent Restenosis in Patients with Coronary Artery Disease and Type 2 Diabetes Mellitus Treated with Percutaneous Coronary Intervention
por: Hu, Cheng-Ping, et al.
Publicado: (2018)

Risk factors of in-stent restenosis among coronary artery disease patients with syphilis undergoing percutaneous coronary intervention: a retrospective study
por: Zhang, Ling, et al.
Publicado: (2021)

Albumin to globulin ratio was associated with in‐stent restenosis and revascularization events after percutaneous coronary intervention
por: Zhang, Rui, et al.
Publicado: (2022)

Factors Affecting In-stent Restenosis in Patients Undergoing Percutaneous Coronary Angioplasty
por: Sajadian, Mostafa, et al.
Publicado: (2018)

Serum glycated albumin is associated with in-stent restenosis in patients with acute coronary syndrome after percutaneous coronary intervention with drug-eluting stents: An observational study
por: Lin, Xiao Long, et al.
Publicado: (2022)

Application of Nanoliposome Alprostadil in the Perioperative Period of Percutaneous Coronary Intervention to Reduce In-Stent Restenosis: A Systematic Review and Meta-Analysis
por: Zhu, Decai, et al.
Publicado: (2023)

Coated stents to prevent restenosis in coronary heart disease
por: Gorenoi, Vitali, et al.
Publicado: (2005)

Drug- and Gene-eluting Stents for Preventing Coronary Restenosis
por: Lekshmi, Kamali Manickavasagam, et al.
Publicado: (2017)

Relationship between ALDH2 genotype and in-stent restenosis in Chinese Han patients after percutaneous coronary intervention
por: Lv, Lizhi, et al.
Publicado: (2019)

A Nomogram for Predicting In-Stent Restenosis Risk in Patients Undergoing Percutaneous Coronary Intervention: A Population-Based Analysis
por: Luo, Yinhua, et al.
Publicado: (2022)

Switching types of drug-eluting stents does not prevent repeated in-stent restenosis in patients with coronary drug-eluting stent restenosis
por: Nojima, Yuhei, et al.
Publicado: (2014)

Hypersensitivity and in-stent restenosis in coronary stent materials
por: Hu, Wansong, et al.
Publicado: (2022)

The characteristics and risk factors of in-stent restenosis in patients with percutaneous coronary intervention: what can we do
por: Wang, Pengfei, et al.
Publicado: (2020)

Development and validation of a risk prediction nomogram for in-stent restenosis in patients undergoing percutaneous coronary intervention
por: He, Wenbo, et al.
Publicado: (2021)

Vascular Endothelial Growth Factor Genetic Variant Is Associated with in-Stent Restenosis after Percutaneous Coronary Intervention
por: Asgarbeik, Saeedeh, et al.
Publicado: (2022)

Correlation between estimated glucose disposal rate and in-stent restenosis following percutaneous coronary intervention in individuals with non-ST-segment elevation acute coronary syndrome
por: Liu, Chi, et al.
Publicado: (2022)

Predictors of restenosis following percutaneous coronary stent implantation: The role of trimetazidine therapy
por: Csató, Gábor, et al.
Publicado: (2022)

Prevalence, predictors, and management for balloon uncrossable or undilatable lesions in patients undergoing percutaneous coronary intervention with in-stent restenosis chronic total occlusion
por: Wang, Yong, et al.
Publicado: (2023)

Clinical characteristics of early and late drug-eluting stent in-stent restenosis and mid-term prognosis after repeated percutaneous coronary intervention
por: Zheng, Jian-Feng, et al.
Publicado: (2020)

The effectiveness of Salvianolate injection for in-stent restenosis after percutaneous coronary intervention: A protocol for systematic review and meta-analysis
por: Zhang, Miao, et al.
Publicado: (2022)

Intravascular imaging in coronary stent restenosis: Prevention, characterization, and management
por: Abouelnour, Amr, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_oa5i7qeikfv05leh57iatptqu0